Mersana has developed highly differentiated and innovative antibody-drug conjugate (ADC) platforms, with both cytotoxic and immunostimulatory payloads, that allow for customization and optimization of ADCs for a given target and indication.

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs.

Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options.

Mersana’s innovative platforms have enabled us to build a pipeline for both Mersana and our collaborators. Our ADCs in preclinical studies and clinical trials are first-in-class molecules that target multiple tumor types with high unmet medical need.

Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options.

Jan 10, 2025 · CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that

Jan 10, 2025 · Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for...

Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for...

3 days ago · About Mersana Therapeutics Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory …

5 days ago · William Blair initiated research coverage of Mersana Therapeutics, Inc. (MRSN $0.57), whose lead program emiltatug ledadotin is an ADC that targets B7-H4; it is in Phase I development for TNBC. The company is also developing a HER2-targeted immune-stimulating ADC, XMT-2056, in a Phase I solid tumor study.